Literature DB >> 728902

Cell and tissue distribution of 14C-labeled pyran copolymer.

J D Papamatheakis, R M Schultz, M A Chirigos, J G Massicot.   

Abstract

The tissue distribution of pyran (maleic anhydride-divinyl ether) copolymer was studied after a single ip injection of 14C-labeled pyran (25 mg/kg) to mice. The pyran showed a reticuloendothelial distribution with the liver and spleen containing the highest concentrations which persisted for at least 21 days after drug treatment. Blood levels of 14C-pyran reached a peak 2 hours after injection and were cleared within 6 hours. Attempts to measure uptake of 14C-pyran by peritoneal macrophages were unsuccessful due to an inability to recover macrophages between 3 and 24 hours after ip pyran administration. Since activated macrophages appear to be the primary mechanism by which pyran enhances host resistance to microbial infection and neoplasia, the uptake of 14C-pyran by isolated peritoneal macrophages in vitro was studied. Purified macrophages showed a gradually increasing uptake of 14C-pyran, and a large amount of cell-associated radioactivity was bound to trichloroacetic acid-precipitable material. Several polyanions, including unlabeled pyran, dextran sulfate, and poly(I)-poly(C), competed for acid-precipitable receptor molecules. The superior antitumor effects of pyran as compared to other polyanions may result from the continuous presence of the synthetic polymer in the host. Possible mechanisms of immunopotentiation by pyran are discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 728902

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  2 in total

1.  Clinical pharmacology of the biological response modifier maleic anhydride divinyl ether copolymer (MVE-2).

Authors:  M G Rosenblum; A M Rios; E M Hersh
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 2.  Experimental glomerulonephritis induced by hydrocarbon exposure: a systematic review.

Authors:  Uffe Ravnskov
Journal:  BMC Nephrol       Date:  2005-12-14       Impact factor: 2.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.